Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Neurotrope, Inc. (NASDAQ: NTRP).

Full DD Report for NTRP

You must become a subscriber to view this report.


Recent News from (NASDAQ: NTRP)

Neurotrope, In Consultation With Leading Neuroscientists, Completes the Study Design for its Confirmatory Phase 2 Trial in Advanced Alzheimer's Patients
NEW YORK , May 7, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), is announcing that Neurotrope Bioscience, Inc., its wholly-owned operating...
Source: PR Newswire
Date: May, 07 2018 08:30
Neurotrope And The Missing Step In Alzheimer's Disease
Neurotrope’s ( NTRP ) bryostatin-1 appears to lead to improvements in cognition and activities of daily living in some late stage Alzheimer’s disease patients, but a critical step is missing. Namely, bryostatin-1 would be much more effective if it were accompanied by compounds th...
Source: SeekingAlpha
Date: March, 13 2018 15:21
Premarket analyst action - healthcare
Cowen, Barclays and ROTH all host healthcare conferences next week. More news on: Anavex Life Sciences Corp., Owens & Minor Inc., Verastem, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: March, 08 2018 08:26
Biogen, Neurotrope, Anavex And The Future Of Alzheimer's Treatments
There are basically two approaches to Alzheimer’s research: the traditional and the non-traditional. The traditional approach focuses on preventing the formation or removing misfolded proteins: amyloid and tau. The non-traditional approach focuses on ameliorating other aspects of Alzhei...
Source: SeekingAlpha
Date: March, 01 2018 07:57
Neurotrope to Present at the Cowen and Company 38th Annual Health Care Conference
NEW YORK , Feb. 28, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that Daniel Alkon , MD, President and Chief Scientific Of...
Source: PR Newswire
Date: February, 28 2018 08:30
Neurotrope to Present at BIO CEO & Investor Conference
NEW YORK , Feb. 7, 2018 /PRNewswire/ --   Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that Daniel Alkon , MD, President and Chief Scientific...
Source: PR Newswire
Date: February, 07 2018 08:30
Neurotrope to Present at NobleCon 14th Annual Institutional Investor Conference
NEW YORK , Jan. 25, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that Dr. Daniel Alkon , President and CSO, will provide a co...
Source: PR Newswire
Date: January, 25 2018 08:30
The Curious Case Of Neurotrope
While most drug companies running clinical trials for Alzheimer’s disease are moving toward testing people in the very early stages of Alzheimer’s disease and at high doses, Neurotrope ( NTRP ) is doing the exact opposite. The company is testing its drug in people with advanced A...
Source: SeekingAlpha
Date: January, 18 2018 04:24
Neurotrope's Bryostatin Improves Cognition in Patients with Advanced Alzheimer's Disease Based on Further Analysis of Phase 2 Clinical Trial Data
NEW YORK , Jan. 5, 2018 /PRNewswire/ --   Neurotrope (NASDAQ: NTRP) today announced that a post-hoc analysis of data from its Phase 2 trial in patients with advanced Alzheimer's disease (AD) found evidence of improvement in cognition in patients receiving the 20μg bryostatin r...
Source: PR Newswire
Date: January, 05 2018 09:28
Neurotrope to Present Additional Findings from Bryostatin Phase 2 Trial in Advanced Alzheimer's Disease
NEW YORK , Dec. 19, 2017 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that it will present additional clinical findings from i...
Source: PR Newswire
Date: December, 19 2017 08:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-189.019.199.468.9171,706
2018-05-179.019.199.468.9171,706

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-171,3043,74634.8105Cover
2018-08-166,44211,95653.8809Short
2018-08-151,6992,81160.4411Short
2018-08-141,3152,20559.6372Short
2018-08-133,9646,25763.3530Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NTRP.


About Neurotrope, Inc. (NASDAQ: NTRP)

Logo for Neurotrope, Inc. (NASDAQ: NTRP)

lt p gt Neurotrope BioScience, Inc. is a specialty biopharmaceutical company developing new therapeutics for the treatment of rare diseases Orphan diseases and Alzheimers Disease. NTRP has also advanced two other Orphan Disease programs using Bryostatin. We are working with the Ichan School of Medicine at Mt. Sinai Hospital in New York to determine the efficacy of Bryostatin for the treatment of Niemann Pick Disease, Type C. In addition, we are also working with the FRAXA Research Foundation to help find a treatment for Fragile X Syndrome using Bryostatin . NTRP licensed the use of Bryostatin for the treatment of Alzheimers Disease as well as other neurodegenerative diseases from the Blanchette Rockefeller Neuroscience Institute BRNI . To date NTRP has successfully completed a first Phase study in moderate Alzheimers patients. We are now conducting a second Phase study. NTRP has also teamed up with Stanford University to find the next generation Bryostatin Bryologs. lt /p gt

 

 

 

Current Management

  • Susanne Wilke / CEO
  • Daniel Alkon / President
    • Dr. Alkon was appointed as our President on September , . Dr. Alkon served as the founding Scientific Director of CRE from until September , . He received his undergraduate degree in chemistry in at the University of Pennsylvania. After earning his M.D. at Cornell University and finishing an internship in medicine at the Mount Sinai Hospital in New York, he joined the staff of the National Institutes of Health where during his year career he became a Medical Director in the U.S. Public Health Service at the National Institute for Neurological Disorders and Strokes and Chief of the Laboratory of Adaptive Systems. From June to September , , Dr. Alkon was the Toyota Chair for Neurodegenerative Disease Research at CRE. In this position, he and his team conducted multidisciplinary research on the molecular and biophysical mechanisms of memory and memory dysfunction in psychiatric and neurological disorders, particularly AD. From October to September , , Dr. Alkon was also a Professor at CRE and a Professor of Neurology at West Virginia University.
  • Robert Weinstein / CFO, Corporate Secretary, EVP
    • Mr. Weinstein joined the Company in June as its acting Chief Financial Officer. He has extensive accounting and finance experience, spanning more than years, as a public accountant, investment banker, healthcare private equity fund principal and chief financial officer. From September to current, Mr. Weinstein has been an independent consultant for several healthcare companies in the pharmaceutical and biotechnology industries. From March to August , he was the Chief Financial Officer of Green Energy Management Services Holdings, Inc., a publiclytraded energy consulting company. From August to February , Mr. Weinstein served as Chief Financial Officer of Xcorporeal, Inc., a publiclytraded, developmentstage medical device company which was sold in March to Fresenius Medical USA, the largest provider of dialysis equipment and services worldwide. Mr. Weinstein received his MBA degree in finance and international business from the University of Chicago Graduate School of Business, is a Certified Public Accountant inactive , and received his BS degree in accounting from the State University of New York at Albany.
  • Paul E. Freiman / Chairman
  • Kenneth J. Gorelick /
  • James Gottlieb /
  • Shana Phares /
  • Joshua Silverman /
  • William Singer /
  • Susanne Wilke /

Current Share Structure

  • Market Cap: $65,790,625 - 03/15/2018
  • Authorized: 12,500,000 - 01/12/2017
  • Issue and Outstanding: 7,907,527 - 02/28/2018
  • Float: 1,627,372 - 01/12/2017

 


Recent Filings from (NASDAQ: NTRP)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: March, 08 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: March, 08 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 06 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 06 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 08 2018

 

 


Daily Technical Chart for (NASDAQ: NTRP)

Daily Technical Chart for (NASDAQ: NTRP)


Stay tuned for daily updates and more on (NASDAQ: NTRP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: NTRP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NTRP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of NTRP and does not buy, sell, or trade any shares of NTRP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/